Angel Biogenics Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Angel Biogenics Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $3.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Angel Biogenics Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $3.4M Trade | TransData Nexus

Angel Biogenics Private Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $3.4M Total Trade · DGFT Verified

Angel Biogenics Private Limited is an Indian pharmaceutical exporter with a total trade value of $3.4M across 5 products in 5 therapeutic categories. Based on 106 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Insulin ($1.7M), Erythromycin ($1.2M), Griseofulvin ($316.9K).

Angel Biogenics Private Limited — Export Portfolio & Destination Treemap

Angel Biogenics Private Limited pharmaceutical export portfolio — 5 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Angel Biogenics Private Limited? — Company Overview & Market Position

Angel Biogenics Private Limited, established on June 26, 2012, is a privately held pharmaceutical company headquartered in Rajkot, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24230GJ2012PTC070913. As of the latest available data, Angel Biogenics has an authorized capital of ₹0.25 million and a paid-up capital of ₹0.25 million. The company is unlisted and operates as a non-government entity. Its registered office is located at Office No. 216/217/218 Anmol, Nr. Raj Palace Sadhuvasvani Road, University Road, Rajkot, Gujarat, 360005.

In the fiscal year ending March 31, 2024, Angel Biogenics reported a significant growth trajectory, with a 47.23% increase in total revenue and a 72.51% rise in profit. The company's net worth also saw a substantial increase of 46.59%. The company employs between 26 to 50 people and has an annual turnover ranging from ₹100 million to ₹500 million.

What Does Angel Biogenics Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Insulin$1.7M 2

Product Portfolio — Top 5 by Export Value

Angel Biogenics Private Limited exports 5 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Insulin	Diabetes & Endocrine	$1.7M	47	2.2%	5
2	Erythromycin	Antibiotics	$1.2M	28	1.6%	10
3	Griseofulvin	Advanced Antifungals	$316.9K	10	0.9%	12
4	Aminophylline	Respiratory & OTC	$85.6K	14	1.5%	9
5	Benzylpenicillin	Advanced Antibiotics	$81.6K	7	2.1%	4

Angel Biogenics Private Limited exports 5 pharmaceutical products across 5 therapeutic categories with a total export value of $3.4M. The top category is Diabetes & Endocrine (49.4% of portfolio), followed by Antibiotics (36.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Angel Biogenics Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Angel Biogenics operates a manufacturing facility located in Shapar (Veraval), Rajkot, Gujarat. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The facility is equipped with advanced technology machinery and tools, enabling the company to produce a diverse range of pharmaceutical products.

3Key Leadership

The leadership team at Angel Biogenics includes:

Sugamkumar Mansukhlal Sureja: Director, appointed on November 6, 2019.

Renuka Sugambhai Sureja: Director, appointed on June 26, 2012.

The company's leadership is committed to maintaining high standards in pharmaceutical manufacturing and export.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Angel Biogenics Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Angel Biogenics has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company exports a diverse portfolio of finished pharmaceutical formulations, such as insulin, erythromycin, griseofulvin, aminophylline, and benzylpenicillin, across five therapeutic categories. In the fiscal year 2022-2026, the company reported a total export value of $3.4 million USD from 106 shipments. The top five products exported include insulin ($1.7 million, 2.2% market share), erythromycin ($1.2 million, 1.6% market share), griseofulvin ($317,000, 0.9% market share), aminophylline ($86,000, 1.5% market share), and benzylpenicillin ($82,000, 2.1% market share).

2Emerging Markets

Angel Biogenics has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's product portfolio includes anticancer agents, antibiotics, anesthetics, antifungals, antidiabetics, and palliative care medications, which are well-suited to meet the healthcare needs of these regions. The company's adherence to international quality standards positions it favorably for market access in these emerging economies.

3Geographic Strategy

Angel Biogenics Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available data, specific details regarding Angel Biogenics' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company continues to focus on enhancing its regulatory compliance to meet the standards of the U.S. Food and Drug Administration.

2WHO & EU GMP

Angel Biogenics adheres to Good Manufacturing Practices (GMP) as outlined by the World Health Organization (WHO) and the European Union (EU). The company's manufacturing processes are designed to meet international quality standards, ensuring the safety and efficacy of its pharmaceutical products. Specific certifications and prequalification statuses are not publicly disclosed.

3CDSCO & Indian Regulatory

Angel Biogenics holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained approvals from state drug controllers. The company has also secured export No Objection Certificates (NOCs), facilitating its international trade operations. These regulatory approvals underscore the company's commitment to maintaining high standards in pharmaceutical manufacturing and export.

Angel Biogenics Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical export sector, Angel Biogenics faces competition from both domestic and international companies. While specific market share comparisons are not publicly available, the company's focus on a diversified product portfolio and adherence to international quality standards position it competitively in the market. The company's strategic emphasis on emerging markets further enhances its competitive edge.

2Key Differentiators

Angel Biogenics' key differentiators include its diversified product portfolio encompassing anticancer agents, antibiotics, anesthetics, antifungals, antidiabetics, and palliative care medications. The company's commitment to quality, adherence to international manufacturing standards, and strategic focus on emerging markets contribute to its competitive advantages. Additionally, the company's proactive approach to regulatory compliance and market expansion further distinguishes it in the pharmaceutical export sector.

3Strategic Position

Angel Biogenics is strategically positioned as a manufacturer and exporter of finished pharmaceutical formulations, with a focus on both generic and specialty products. The company's future outlook includes expanding its presence in emerging markets, enhancing its product portfolio, and strengthening its regulatory compliance to meet international standards. This strategic direction aims to drive sustainable growth and establish the company as a reliable partner in the global pharmaceutical industry.

Buyer Due Diligence Brief — Evaluating Angel Biogenics Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Angel Biogenics has demonstrated a consistent track record in pharmaceutical manufacturing and export, with a total export value of $3.4 million USD from 106 shipments in the fiscal year 2022-2026. The company's product portfolio is diversified across five therapeutic categories, indicating a balanced approach to market demand. The company's adherence to international quality standards and proactive regulatory compliance further enhance its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.

WHO-GMP Certification: Verify adherence to Good Manufacturing Practices as outlined by the World Health Organization.

EU GMP Certification: Ensure compliance with Good Manufacturing Practices recognized by the European Union.

Frequently Asked Questions — Angel Biogenics Private Limited

How many pharmaceutical products does Angel Biogenics Private Limited export from India?

Angel Biogenics Private Limited exports 5 pharmaceutical products across 5 therapeutic categories. The top exports are Insulin ($1.7M), Erythromycin ($1.2M), Griseofulvin ($316.9K), Aminophylline ($85.6K), Benzylpenicillin ($81.6K). Total export value is $3.4M.

What is Angel Biogenics Private Limited's total pharmaceutical export value?

Angel Biogenics Private Limited's total pharmaceutical export value is $3.4M, based on 106 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Angel Biogenics Private Limited cover?

Angel Biogenics Private Limited exports across 5 therapeutic categories. The largest are Diabetes & Endocrine (49.4%, 1 products), Antibiotics (36.5%, 1 products), Advanced Antifungals (9.3%, 1 products).

Get Full Angel Biogenics Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.